NICE

Showing 15 posts of 866 posts found.

Afinitor iimage

Novartis’ Afinitor fails NICE test

July 8, 2013
Sales and Marketing Afinitor, NHS, NICE, Novartis

Novartis’ breast cancer drug Afinitor (everolimus) has been knocked back by NICE as “it is not good value for money”. …

Lords image

Lords: ‘Simplify pharma regulation’

July 1, 2013
Sales and Marketing Lords, NICE, pharma, regulation

Investors are not putting their money into the UK’s regenerative medicine sector because of the high failure rate when it …

evista image

NICE finalises tamoxifen guidance

June 26, 2013
Sales and Marketing Evista, NICE, lilly, tamoxifen

Women at risk of breast cancer can now be offered a daily pill on the NHS to stop the disease …

Forxiga image

NICE completes Forxiga U-turn

June 26, 2013
Sales and Marketing BMS, Forxiga, NICE

Bristol-Myers Squibb and AstraZeneca are celebrating after NICE reversed its decision from earlier this year and is now recommending their …

Haslam image

David Haslam: a new chairman for a new NICE

June 24, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Hasmam, NHS, NICE

When NICE was first set up in 1999, technology appraisals of new medicines were its sole focus, but over the …

CQC revelations continue

June 21, 2013
Sales and Marketing CQC, NHS, NICE

The turmoil at the Care Quality Commission (CQC) shows no sign of abating as MPs may summon the current leadership …

Zaltrap image

Zaltrap ‘no’ from NICE

June 21, 2013
Sales and Marketing NICE, Sanofi, Zaltrap

NICE is preparing to discard Sanofi’s Zaltrap as an NHS option for treating metastatic colorectal cancer (mCRC) that is resistant …

NICE image

UK government keen to reduce drugs bill

June 21, 2013
Sales and Marketing NHS, NICE, UK, VBP

The government has shown its hand in the drug pricing debate after asking for a 20% price cut on some …

Iluvien gets NHS nod

June 14, 2013
Sales and Marketing Iluvien, NHS, NICE, alimera

NICE is gearing up to allow Alimera Sciences’ implant Iluvien to be used on the NHS as an option to …

Abilify image

NICE thumbs-up for Abilify

June 7, 2013
Sales and Marketing Abilify, BMS, NICE, Otsuka

Adolescents who suffer from bipolar disorder should be treated on the NHS with Otsuka Pharmaceuticals’ Abilify, according to draft guidance …

Eylea image

NICE green light for Eylea

May 31, 2013
Sales and Marketing Bayer, NICE, Regeneron

NICE has recommended Bayer’s injection Eylea as a treatment for neovascular (wet) age-related macular degeneration (AMD) if the manufacturer offers …

Goldacre image

Bad pharma, good pharma: an insider’s view

May 30, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Bad pharma, Goldacre, NICE, transparancy

Most people in the pharmaceutical industry, particularly in the UK, will be well-acquainted with Ben Goldacre by now. He published his …

Forxiga image

NICE U-turn on Forxiga

May 30, 2013
Sales and Marketing Forxiga, NICE

NICE has recommended Bristol-Myers Squibb and AstraZeneca’s diabetes drug Forxiga in final draft guidance after turning its back on the …

NICE image

Grant NICE greater trial data access – report

May 29, 2013
Research and Development, Sales and Marketing Goldacre, NICE, transparency, trials

A new report by the National Audit Office says NICE should be given greater powers to access clinical trial data. …

rawlins_nice

NICE chairman joins biotech Board

May 17, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Intra-Cellular Therapies, NICE, Rawlins

Biotech firm Intra-Cellular Therapies has appointed former NICE chairman Professor Sir Michael Rawlins to its Board of directors. Rawlins was …

The Gateway to Local Adoption Series

Latest content